Key Takeaways
- HSBC moved Eli Lilly (LLY) from Hold to Reduce, lowering the price target from $1,070 down to $850
- Analyst Rajesh Kumar argues the stock is “priced to perfection” following a 20% climb in the last year
- HSBC reduced its obesity treatment market projection to $80–120bn by 2032, significantly below the $150bn+ consensus
- Questions arise about orforglipron’s launch potential, pricing dynamics, and dependence on direct-pay consumers
- LLY shares declined 1.6% to $972.51 post-downgrade; competitor Novo Nordisk (NVO) has plunged 52% in the same timeframe
Eli Lilly has enjoyed impressive momentum. While its shares climbed 20% over the past year, competitor Novo Nordisk saw its stock crater by more than half—making LLY appear to be dominating the obesity treatment space. However, HSBC believes the enthusiasm may have outpaced reality.
This Tuesday, HSBC’s Rajesh Kumar lowered his rating on Lilly from Hold to Reduce while slashing the price objective from $1,070 to $850. Shares responded with a 1.6% decline, closing at $972.51.
Kumar’s central thesis is straightforward: the valuation leaves virtually no margin for disappointment.
Three primary issues underpin the downgrade. First is the actual size of the obesity pharmaceutical market. HSBC now projects a total addressable market between $80 billion and $120 billion by 2032. This stands considerably below the $150 billion-plus figure that has become standard among Wall Street analysts.
This discrepancy is significant. A more constrained market ceiling implies less potential for the revenue expansion already reflected in Lilly’s current share price.
Orforglipron Sales Projections Appear Optimistic
The second issue involves Lilly’s forthcoming oral obesity medication, orforglipron. Set for release later this year, the treatment has sparked considerable market enthusiasm—with consensus projections for 2026 sales ranging from $1.1 billion to $1.3 billion.
HSBC believes these figures are inflated. Kumar cautioned that “the compliance and persistence of these drugs might disappoint,” observing that current estimates seem tied to a $1.5 billion inventory stockpile Lilly has already accumulated in preparation for launch.
While inventory buildup signals corporate confidence, it simultaneously elevates risk if actual demand falls short of expectations.
Pricing Headwinds Emerging
The third challenge centers on pricing dynamics. Lilly confronts potential price reductions in 2026 due to intensifying competition, with HSBC highlighting “rising working capital intensity” and weakening “rebate dynamics” as red flags.
Kumar also addressed the performance disparity between Lilly and Novo Nordisk’s projections—a puzzle for many market observers. His interpretation suggests Lilly’s superior results stem from its heavy reliance on the cash-pay segment, where patients purchase medications without insurance coverage.
This segment demonstrates greater vulnerability to economic fluctuations and, according to HSBC, faces potential disruption from AI-driven labor market transformations.
HSBC maintains a constructive outlook on the broader healthcare industry for the coming quarter. However, Kumar sees Lilly’s current risk-reward profile as unattractive given present valuation levels.
LLY traded at $972.51 when the downgrade was issued, representing more than $120 above HSBC’s revised $850 target price.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
